Why is Reimbursement Failing to Support Precision Medicine?

This year I had the opportunity to be the chairperson and one of the speakers during the International Molecular Diagnostics Congress in Barcelona, an event that brought together several experts from industry, including government and other stakeholders, to discuss the recent advances in precision medicine (or personalized medicine) and its clinical and economic implications to healthcare.

As explained by the US Department of Health and Human Services, “Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person”.

The goal of precision medicine is to create more effective and cost-efficient treatment approaches that may reduce costs, whilst demonstrating improved outcomes. Sounds great, right? No, not for the current reimbursement systems.

In spite of the strong potential benefits, reimbursement remains the #1 barrier for precision medicine, as validated unanimously at the International Molecular Diagnostics Congress in Barcelona.

Click here to read the full post in our blog.